D
바이오다인
314930KOSDAQ37.5 / 100
Reference Date: 2026-09-08
Financial Score11.0 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: PER raises overvaluation concerns, PBR raises overvaluation concerns. Declined 14.4% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
BioDain develops, manufactures, and sells liquid-based cytology (LBC) equipment and cancer diagnostic kits, leveraging its proprietary Blowing Technology to enhance diagnostic accuracy and usability. The company exports its products to 13 countries, including Japan, the U.S., and Europe, and collaborates with Roche to develop the VENTANA SP400 device, expanding its global market presence.
Number of Employees
23people
Average Salary
39.1M KRW
Score Calculation Basis
Detailed Financial Score
PER
244.48Industry Average 15.000.0Point
16.3x industry avg (risky)
PBR
4.79Industry Average 1.200.0Point
4.0x industry avg (risky)
ROE
1.95Industry Average 8.001.0Point
Well below industry avg
Debt Ratio
—Industry Average 100.004.0Point
Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲31.1% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲76.7% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -0.1% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (1%, downtrend)
Current 7,090Won52-week high 16,31052-week low 6,940
1-month return1.0Point
1m -14.37% (falling)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-08-14
- Neutral반기보고서 (2026.06)2026-08-14